To this point, most of the successful attempts of ICI usage in cancers like liver cancer were demonstrated in combination or when pre-treated with small molecule tyrosine kinase inhibitors, suggesting the potential of cMET inhibitors when evolved in combination with ICIs in mUM patients (48, 49). This evidence concerns the gene MET and liver cancer.